NIBRT - The National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merion, Blackrock Co., Dublin A94 X099, Ireland.
Mol Omics. 2019 Feb 11;15(1):7-20. doi: 10.1039/c8mo00193f.
Multiple myeloma, an incurable malignancy of the plasma cells in the bone marrow, has a complex pathogenesis due to clonal heterogeneity. Over the years, many clinical trials and researches have led to the development of effective myeloma treatments, resulting in survival prolongation. Molecular prognostic markers for risk-stratification to predict survival, and predictive markers for treatment response are being extensively explored. This review discusses the current risk-adaptive strategies based on genetic and molecular risk signatures that are in practice to predict survival and describes the future prognostic and predictive biomarkers across the fields of genomics, proteomics, and glycomics in myeloma. Gene expression profiling and next generation sequencing are coming to the forefront of risk-stratification and therapeutic-response prediction. Similarly, proteomic and glycomic-based platforms are gaining momentum in biomarker discovery to predict drug resistance and disease progression.
多发性骨髓瘤是一种骨髓浆细胞的不可治愈的恶性肿瘤，由于克隆异质性而具有复杂的发病机制。多年来，许多临床试验和研究导致了有效的骨髓瘤治疗方法的发展，从而延长了生存期。目前正在广泛探索用于预测生存的分子预后标志物和治疗反应的预测标志物。本文讨论了目前基于遗传和分子风险特征的适应性风险策略，这些策略用于预测生存，并描述了骨髓瘤领域中基因组学、蛋白质组学和糖组学的未来预后和预测生物标志物。基因表达谱分析和下一代测序正在成为风险分层和治疗反应预测的前沿。同样，基于蛋白质组学和糖组学的平台也在生物标志物发现方面取得了进展，以预测耐药性和疾病进展。
